• Prof Henri Bounameaux, Dean, Faculty of Medicine, University of Geneva and Director of Education and Research, University Hospitals of Geneva (CH)
  • Prof Henri Bounameaux

    Dean, Faculty of Medicine, University of Geneva and Director of Education and Research, University Hospitals of Geneva (CH)

    Henri Bounameaux is Professor of medicine, Dean of the Faculty of Medicine of the University of Geneva (since 2011), and Director of Education and Research at the University Hospitals of Geneva (HUG). In the latter capacity, he seats in the Board of directors of the HUG. He studied medicine in Basel and obtained his MD from the University of Basel in 1978. After his medical residency in Geneva, Basel and Montreux and a post-doc in Leuven (Belgium), he joined the Division of Angiology and Hemostasis of the University Hospitals of Geneva in 1985. Henri Bounameaux was appointed director of the Division in 1993, a role he assumed until 2015 when he gave up this function and became Senior Consultant in the division. From 2002 to 2010 he also chaired the Department of Internal Medicine. Henri Bounameaux’s research interests cover all aspects of venous thromboembolism, from epidemiology and diagnosis to prevention and treatment. He has authored more than 400 papers in peer-reviewed journals, and acts as a reviewer in many journals in the field of internal and vascular medicine. He was a panellist of the 9th and 10th editions of the American College of Chest Physicians (ACCP) guidelines on antithrombotic treatments.. He was President of the International Society on Thrombosis and Haemostasis (ISTH) Congress in Geneva in 2007, and served as Chairman of the Council of ISTH during the period 2010-2012. He has received several awards including the Karl Rohr Prize of the Swiss Society of Hematology (1991), the Swiss Angiology Prize (1991), the Theodor Naegeli International Thrombosis Award (1995), an Investigator recognition Award (2003) and a Distinguished Career Award (2009) from the ISTH, and he is a member of the Swiss Academy of Medical Sciences.

  • Prof Samia Hurst, Director, Institute of Ethics, History and Humanities (iEH2), Faculty of Medicine, University of Geneva (CH)
  • Prof Samia Hurst

    Director, Institute of Ethics, History and Humanities (iEH2), Faculty of Medicine, University of Geneva (CH)

    Samia Hurst is a professor of Bioethics at the Faculty of Medicine of the University of Geneva. She obtained a doctoral degree in medicine from the University of Geneva in 2001, and did a specialization in internal medicine. From 2001 to 2003, Samia Hurst was a post-doctoral fellow in the Department of Clinical Bioethics at the US National Institutes of Health in Bethesda. In 2010 she obtained a privat-docent in Bioethics from the University of Geneva, and was appointed ordinary professor in 2013. Since 2015 she is the director of the Institute of Ethics, History and Humanities (iEH2) of the Faculty of Medicine. Samia Hurst research interests include the ethical issues of clinical practice, clinical research and health policies. Her work focuses on questions related to fairness and the protection of vulnerable persons. Samia Hurst is an ethics consultant at the clinical ethics committee of the University Hospitals of Geneva and since 2015 she oversees the Clinical Ethics Unit of the Lausanne University Hospital. She is a founding member of the European Clinical Ethics Network, and a member of several research ethics committees, including the Central Ethics Committee of the Swiss Academy of Medical Sciences and the Swiss National Advisory Commission on Biomedical Ethics.

  • Prof Thomas Perneger, Head of Unit, Division of Clinical Epidemiology and Methodological Support Unit, Clinical Research Center (CRC), University Hospitals of Geneva and University of Geneva (CH)
  • Prof Thomas Perneger

    Head of Unit, Division of Clinical Epidemiology and Methodological Support Unit, Clinical Research Center (CRC), University Hospitals of Geneva and University of Geneva (CH)

    Thomas Perneger studied medicine at the University of Geneva and completed a specialization in internal medicine. Having became interested in a more global perspective on health, he obtained a Master degree in public health (MPH, 1989), a Master degree in biostatistics (MHS, 1991) and a doctoral degree in epidemiology (PhD, 1993) from the Johns Hopkins University, Baltimore (USA). Upon returning to Geneva he focused on the evaluation of health services, and directed the Quality of care service at University Hospitals of Geneva between 1997 and 2007; during that time he was active in quality of care and patient safety policy at the national and international levels (working group member at the Council of Europe and World Health Organization, editor of the International Journal for Quality in Health Care). Since 2007 Thomas Perneger has directed the Division of Clinical Epidemiology and the Methodological Support Unit of the Clinical Research Center at the University Hospitals of Geneva. Thomas Perneger was appointed associate professor at the Faculty of Medicine in 2001 and full professor in 2008. His main research interests include medical research methods, quality and safety of health care, and patients’ involvement in clinical management. He has authored over 200 scientific publications, and contributed to several books on epidemiology. He is a member of the DAS in Management of Clinical Trials Steering Committee and the director of the CAS in Patient-oriented Clinical Research.

  • Prof Jérôme Pugin, Vice-Dean in charge of clinical medicine and clinical research, Faculty of Medicine, University of Geneva, Director of the Clinical Research Center and Head of Unit, Intensive Care Division, University Hospitals of Geneva (CH)
  • Prof Jérôme Pugin

    Vice-Dean in charge of clinical medicine and clinical research, Faculty of Medicine, University of Geneva, Director of the Clinical Research Center and Head of Unit, Intensive Care Division, University Hospitals of Geneva (CH)

    Jérôme Pugin obtained his medical degree from the University of Geneva in 1984. He did a specialization in internal medicine and in intensive care. His clinical activities focus on intensive care and he was appointed head of the Intensive Care Division of the University Hospitals of Geneva in 2014. Jerôme Pugin is also the head of the Laboratory of Research of Intensive Care, at the Faculty of Medicine of Geneva University. His research interests have focused over the last years on the molecular and cellular pathogenesis of sepsis. He has been interested in soluble proteins involved in the innate recognition of bacteria such as soluble CD14 and MD-2, as well as in the Toll-like receptors activated by Gram-negative and Gram-positive bacteria. He has also been studying the molecular pathogenesis and cell signaling of ventilator-induced lung injury, and lung inflammation in the context of the acute respiratory distress syndrome. Another important research interest of Jerôme Pugin is the biomarkers of sepsis, and in particular the usefulness of procalcitonin in the diagnosis of sepsis and its use to guide antibiotic therapy in the Intensive Care Unit (ICU). Since 2010, he has also been involved in a humanitarian project with various hospitals in Cuba, and has developed a program for medical students in la Habana. In 2011, Jérôme Pugin was appointed ordinary professor at the department of Anesthesiology, Pharmacology and Intensive Care of the Faculty of Medicine, University of Geneva. He is co-chair of the Faculty’s permanent commission on research, and participates in many committees for recruitment of new professors in the Faculty.

  • Prof Gerrit Borchard, Professor, Section of Pharmaceutical Sciences, Biopharmaceutical Sciences, University of Geneva (CH)
  • Prof Gerrit Borchard

    Professor, Section of Pharmaceutical Sciences, Biopharmaceutical Sciences, University of Geneva (CH)

    Gerrit Borchard is a licensed pharmacist and obtained his Ph.D. in pharmaceutical technology from the University of Frankfurt (Germany) for his thesis on the interaction of colloidal drug carrier systems with the immune system. After holding several academic posts, including a lecturer position at Saarland University (Germany) and Assistant and Associate Professorships at Leiden University (The Netherlands), he joined Enzon Pharmaceuticals, Inc. (USA) as Vice President Research in 2003. In 2005, he was appointed Full Professor of Biopharmaceutics at the University of Geneva and Scientific Director of the Centre Pharmapeptides in Archamps (France), an international center for biopharmaceutical research and training. Gerrit Borchard is (co-)author of over 130 scientific publications and book chapters, co-editor of one book and named as inventor on seven patents. His research interests relate to formulation of macromolecules, the development of mucosal vaccines and the characterization of nano-sized carriers as drug delivery systems. From 2008 to 2013, he served as Vice President of the School of Pharmaceutical Sciences Geneva-Lausanne (EPGL) and from 2013 to 2014 as acting president. In 2012 Prof Borchard joined the Non Biological Complex Drugs (NBCD) working group hosted at Lygature (former Top Institute Pharma (TIP, Leiden, The Netherlands), and became member of the steering committee in 2015. He was nominated Chair of the NBC working party at the European Directorate for the Quality of Medicines & Health Care (EDQM) by Swissmedic in 2013. Prof Borchard was nominated Fellow of the Swiss Society of Pharmaceutical Sciences (SSPhS) in 2010, and has been President of the Swiss Academy of Pharmaceutical Sciences since 2014. He also served as Vice President of the European Federation of Pharmaceutical Sciences (EUFEPS) from 2013 to 2015.

  • Prof Arnaud Perrier, Medical Director, University Hospitals of Geneva (CH)
  • Prof Arnaud Perrier

    Medical Director, University Hospitals of Geneva (CH)

    Arnaud Perrier studied medicine in the Faculty of Medicine of the University of Geneva, from which he graduated in 1982. After two years of basic research in renal physiology, he specialized in internal medicine and in pneumology in the University Hospitals of Geneva. He returned to a full time position in internal medicine in 1994 and headed the Division of General Internal Medicine from 2004 to 2016 and of the Department of Internal Medicine, Rehabilitation and Geriatrics in the University Hospitals of Geneva from 2011 to 2015. Arnaud Perrier’s main research interests cover the field of venous thromboembolism, with the perspective of developing validated diagnostic and cost-effective diagnostic strategies. He has co-authored more than 200 papers in peer-reviewed journals. His interests encompass medical education and he participated actively to the development and implementation of the new pre-graduate curriculum of the Faculty of Medicine in Geneva. He participated to the Harvard Macy scholarship program for physician educators in 1999. Arnaud Perrier was a member of the Governing board of the Swiss Academy of medical Sciences. He has been a prominent member of the Guidelines Taskforce of the European Society of Cardiology for pulmonary embolism. He presided the congress of the Swiss Society of Internal Medicine and European Federation of Internal Medicine in Geneva in 2014.

  • Prof Jules Desmeules, Head of Unit, Division of Clinical Pharmacology and Toxicology and Clinical Trial Unit, Clinical Research Center (CRC), University Hospitals of Geneva and University of Geneva (CH).
  • Prof Jules Desmeules

    Head of Unit, Division of Clinical Pharmacology and Toxicology and Clinical Trial Unit, Clinical Research Center (CRC), University Hospitals of Geneva and University of Geneva (CH)

    Jules Desmeules studied in Geneva and obtained is MD from the University of Geneva in 1991. After spending a few years in France, where he studied molecular pharmacochemistry, experimental pharmacology, and metabolism, he specialized in internal medicine and in clinical pharmacology and toxicology. In 2008, Jules Desmeules was appointed ordinary professor at the Faculty of Medicine of the University of Geneva. His research is mostly concerned with the study of drug transportation and the enzymes involved in the metabolism of xenobiotics such as cytochromes P450 through in vitro (microsomes, cells) or in vivo models (phenotypisation, genotypisation, pharmacokinetic, toxicogenetic and pharmacogenetic studies). His other main research topics center on the development of neurophysiological evaluation methods for testing the efficacy of peripheral and central analgesics (psychometric and neurophysiological-quantitative sensory testing evaluation), and screening dysfunctions in the transmission and modulation systems involved in chronic pain syndromes. Jules Desmeules regularly publishes in the top venues of pharmacology and toxicology journals, has more than 3000 citations and an h-index of 28. He is the director of the Master of Advanced Study (MAS) in Toxicology, the MAS in Drug Discovery and Clinical Development and the Diploma of Advanced Studies (DAS) in Management of Clinical Trials of the University of Geneva.

  • Prof Bernard Hirschel, Chair, Cantonal Commission on Human Research Ethics, Canton of Geneva (CH)
  • Prof Bernard Hirschel

    Chair, Cantonal Commission on Human Research Ethics, Canton of Geneva (CH)

    Bernard Hirschel is the chair of the Cantonal Commission on Human Research Ethics which reviews all medical research proposals involving human subjects in Geneva, Switzerland. After graduating from the Faculty of Medicine of the University of Geneva, he pursued postgraduate studies in internal medicine and infectious diseases in Geneva, and at Washington University in St. Louis, USA. After his return to Switzerland, he involved himself in the nascent AIDS epidemic. Until his retirement in 2011, he was head of the HIV/AIDS Division, and director of the Clinical Research Center at the University Hospitals of Geneva. He contributed to seminal studies establishing the effectiveness of prevention of opportunistic infections, and discovered a novel pathogenic microorganism, Mycobacterium genavense. With the advent of effective medications, his focus shifted from opportunistic infections to anti-retroviral therapy. His particular interests involved novel treatment strategies, particularly planned interruption of anti-retroviral therapy, and the use of treatment in preventing new HIV infections. Bernard Hirschel is the author or co-author of some 300 papers in the scientific literature, of book chapters, and of a textbook on HIV infection. He was a member of several editorial boards, including the New England Journal of Medicine from 1998 to 2006, and of numerous scientific societies.